yingweiwo

Oxaliplatin (Eloxatin; L-OHP; JM-83; RP-54780; SR-96669)

Alias: L-OHP; diaminocyclohexane oxalatoplatinum; oxalatoplatin; oxalatoplatinum; DTXSID0036760; Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II); cis-oxalato-trans-l-1,2-diaminocyclohexaneplatinum(II); US brand name: Eloxatin Foreign brand names: Dacotin; Dacplat; Eloxatine; Abbreviations: 1OHP; LOHP; Code names: JM83; RP54780; SR96669.
Cat No.:V0057 Purity: ≥98%
Oxaliplatin (Eloxatin; L-OHP; JM83; RP54780; SR96669),an anticancer drug used for treating colorectal cancer,is an organoplatinum complex (1,2-diaminocyclohexane (DACH) and with an oxalate ligand), acnting by inhibiting DNA synthesis by forming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Oxaliplatin (Eloxatin; L-OHP; JM-83; RP-54780; SR-96669)
Oxaliplatin (Eloxatin; L-OHP; JM-83; RP-54780; SR-96669) Chemical Structure CAS No.: 61825-94-3
Product category: DNA(RNA) Synthesis
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
100mg
500mg
1g
2g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Oxaliplatin (Eloxatin; L-OHP; JM83; RP54780; SR96669), an anticancer drug used for treating colorectal cancer, is an organoplatinum complex (1,2-diaminocyclohexane (DACH) and with an oxalate ligand), acnting by inhibiting DNA synthesis by forming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. As a leaving group, an oxalate ligand and DACH form a complex with the platinum atom of oxaliplatin. Once the labile oxalate ligand has left the group, active oxaliplatin derivatives, like monoaquo and diaquo DACH platinum, alkylate macromolecules to form inter- and intra-strand platinum-DNA crosslinks. These crosslinks inhibit DNA replication and transcription and cause non-specific cytotoxicity that is specific to the cell cycle.

Biological Activity I Assay Protocols (From Reference)
Targets
DNA synthesis; DNA alkylation
ln Vitro

Oxaliplatin's primary mode of action is mediated by the creation of DNA adducts. Cell death is caused by primary and secondary DNA lesions induced by oxaliplatin. Oxaliplatin has an IC50 of 0.98 mM and 0.14 mM, respectively, against the human melanoma cell lines C32 and G361. With IC50 values of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM, and 7.85 μM, respectively, Oxaliplatin effectively inhibits the bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144.

ln Vivo
With sham treatment, TTc transport causes fluorescent signal intensity over the thoracic spine to increase from 0 to 60 minutes after injection. On average, fluorescence signal increased 722%+/-117% (Mean+/-SD) from 0 to 60 minutes. Oxaliplatin treated animals had comparable transport at baseline (787%+/-140%), but transport rapidly decreased through the course of the study, falling to 363%+/-88%, 269%+/-96%, 191%+/-58%, 121%+/-39%, 75%+/-21% with each successive week and stabilizing around 57% (+/-15%) at 7 weeks. Statistically significant divergence occurred at approximately 3 weeks (p≤0.05, linear mixed-effects regression model). Quantitative immuno-fluorescence histology with a constant cutoff threshold showed reduced TTc in the spinal cord at 7 weeks for treated animals versus controls (5.2 Arbitrary Units +/-0.52 vs 7.1 AU +/-1.38, p<0.0004, T-test). There was no significant difference in neural cell mass between the two groups as shown with NeuN staining (10.2+/-1.21 vs 10.5 AU +/-1.53, p>0.56, T-test). Conclusion: We show-for the first time to our knowledge-that neurographic in vivo molecular imaging can demonstrate imaging changes in a model of oxaliplatin-induced neuropathy. Impaired retrograde neural transport is suggested to be an important part of the pathophysiology of oxaliplatin-induced neuropathy. [6]
Oxaliplatin, administered intraperitoneally (i.p.) once a week at a dose of 10 mg/kg, dramatically lowers the tumor volume and apoptotic index in nude mice with hepatocellular HCCLM3 tumors. T-leukemia-lymphoma L40 AKR response to Oxaliplatin (5 mg/kg, i.v. on days 1, 5, and 9) is 1.77 T/C. Additionally, Oxaliplatin works well on xenografts of B16 melanoma, MA 16-C melanoma, Lewis lung xenografts, C26 colon carcinoma, and intracerebrally grafted L1210 leukemia. n mice, Oxaliplatin causes impairment of retrograde neuronal transport.
Cell Assay
The sulforhodamine-B microculture colorimetrie assay is used to conduct the cytotoxicity investigations. The sulforhodamine-B test is typically conducted 48 hours after the cells (RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cell lines) are plated into 96-well plates on day 0 and exposed to oxaliplatin on day 1. Except for when adding oxaliplatin and during the final assay period, the plates are always incubated at 37 °C in 5% CO2 and 100% relative humidity. The assay started with 2–20 × 103 cells/50 nL/well plated on a slide. On the day of the assay, the cells in control wells must still be in the log phase of growth; the maximum absorbance for the untreated controls must fall between 1.0 and 1.5; and the cells must undergo more than two doublings during the drug exposure. These criteria are based on pilot studies. A concentration is made up of eight wells. Using an IBM PC-compatible computer as the interface, a Biotek Instruments model EL309 microplate reader is used to read the plates at 570–540 nm. The computer program DATALOG transfers the data and converts it into a LOTUS 1-2-3 format. The drug treated and control are compared to determine the survival fractions.
Animal Protocol
Mice (n = 8/group) were injected with a cumulative dose of 30 mg/kg oxaliplatin (sufficient to induce neurotoxicity) or dextrose control injections. Intramuscular injections of Tetanus Toxin C-fragment (TTc) labeled with Alexa 790 fluorescent dye were done (15 ug/20 uL) in the left calf muscles, and in vivo fluorescent imaging performed (0–60 min) at baseline, and then weekly for 5 weeks, followed by 2-weekly imaging out to 9 weeks. Tissues were harvested for immunohistochemical analysis.[6]
Researchers used two groups of 8 BALB/C mice for imaging studies: controls and oxaliplatin treatment (16 animals total for imaging studies). An additional two groups of 4 animals each were used for histological studies (8 animals total for histology), euthanized 7 weeks after starting the oxaliplatin regimen. Using a well-characterized model system described in the literature, experimental animals received Oxaliplatin dissolved in sterile water at 1 mg/ml (diluted as needed in 5% glucose) at a dose of 3 mg/kg per intra-peritoneal injection (0.2 ml total) for 5 days during the first week, followed by a 7 day rest, followed by another series of 5 daily injections in the third week. The total dose was 30 mg/kg cumulative, spread out over 10 injections given in two cycles. Control animals received 5% glucose sham injections. Animal weights were determined once a week at the end of the week prior to injections.[6]
Dissolved in water; 10 mg/kg; i.p. injection.
Human hepatocellular carcinoma xenografts HCCLM3
ADME/Pharmacokinetics
Absorption
The reactive oxaliplatin derivatives are present as a fraction of the unbound platinum in plasma ultrafiltrate. After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m2, pharmacokinetic parameters expressed as ultrafiltrable platinum was Cmax of 0.814 mcg/mL. Interpatient and intrapatient variability in ultrafiltrable platinum exposure (AUC0-48hr) assessed over 3 cycles was 23% and 6%, respectively.

Route of Elimination
The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of ELOXATIN, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%.

Volume of Distribution
After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m2, the volume of distribution is 440 L.At the end of a 2-hour infusion, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine.

Clearance
Platinum was cleared from plasma at a rate (10-17 L/h) that was similar to or exceeded the average human glomerular filtration rate (GFR; 7.5 L/h). The renal clearance of ultrafiltrable platinum is significantly correlated with GFR.
Metabolism / Metabolites
Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation. There is no evidence of cytochrome P450-mediated metabolism in vitro. Up to 17 platinum-containing derivatives have been observed in plasma ultrafiltrate samples from patients, including several cytotoxic species (monochloro DACH platinum, dichloro DACH platinum, and monoaquo and diaquo DACH platinum) and a number of noncytotoxic, conjugated species.
Biological Half-Life
The decline of ultrafilterable platinum levels following oxaliplatin administration is triphasic with two distribution phases: t1/2α; 0.43 hours and t1/2β; 16.8 hours. This is followed by a long terminal elimination phase that lasts 391 hours (t1/2γ).
Toxicity/Toxicokinetics
Hepatotoxicity
Mild and transient elevations in serum aminotransferase levels are found in an appreciable proportion of patients taking oxaliplatin, but their relationship to oxaliplatin is often unclear. Chemotherapy with oxaliplatin has been associated with histological changes in the liver marked by sinusoidal dilatation, congestion and centrolobular necrosis indicative of sinusoidal obstruction syndrome. These changes are usually mild-to-moderate in severity and not clinically significant during the acute phase, but they can progress to clinically apparent sinusoidal obstruction syndrome or, with chronic therapy, to nodular regenerative hyperplasia with splenomegaly, thrombocytopenia and esophageal varices. Nodular regenerative hyperplasia typically requires 6 to 18 months to develop and arises after repeated cycles of chemotherapy with oxaliplatin. Serum enzyme and bilirubin elevations are minimal, the major laboratory finding being a progressive and persistent thrombocytopenia reflecting the development of splenomegaly and portal hypertension. The first clinical evidence of nodular regenerative hyperplasia may be ascites, esophageal variceal hemorrhage or hepatic encephalopathy. Attempts at hepatic resection, severe gastrointestinal bleeding and septicemia may trigger hepatic decompensation and liver failure. Interestingly, nodular regenerative hyperplasia and portal hypertension tend to improve slowly once chemotherapy is stopped, but the long term consequences of the changes are not well defined.
Likelihood score: A (well established cause of clinically apparent liver injury).
Protein Binding In patients, plasma protein binding of platinum is irreversible and is greater than 90%. The main binding proteins are albumin and gamma-globulins. Platinum also binds irreversibly and accumulates (approximately 2-fold) in erythrocytes, where it appears to have no relevant activity. No platinum accumulation was observed in plasma ultrafiltrate following 85 mg/m2 every two weeks.
References

[1]. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71.

[2]. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11(10):859-63.

[3]. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6.

[4]. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604.

[5]. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. Biomed Pharmacother. 1989;43(4):237-50.

[6]. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.

[7]. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11987-92.

[8]. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10):1433-40.

[9]. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347.

Additional Infomation
An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane, and with an oxalate ligand which is displaced to yield active oxaliplatin derivatives. These derivatives form inter- and intra-strand DNA crosslinks that inhibit DNA replication and transcription. Oxaliplatin is an antineoplastic agent that is often administered with FLUOROURACIL and FOLINIC ACID in the treatment of metastatic COLORECTAL NEOPLASMS.
See also: Oxaliplatin (annotation moved to).
Of the new generation platinum compounds that have been evaluated, those with the 1,2-diaminocyclohexane carrier ligand-including oxaliplatin--have been focused upon in recent years. Molecular biology studies and the National Cancer Institute in vitro cytotoxic screening showed that diaminocyclohexane platinums such as oxaliplatin belong to a distinct cytotoxic family, differing from cisplatin and carboplatin, with specific intracellular target(s), mechanism(s) of action and/or mechanism(s) of resistance. In phase I trials, the dose-limiting toxicity of oxaliplatin was characterized by transient acute dysesthesias and cumulative distal neurotoxicity, which was reversible within a few months after treatment discontinuation. Moreover, oxaliplatin did not display any, auditory, renal and hematologic dose-limiting toxicity at the recommended dose of 130 mg/m2 q three weeks or 85 mg/m2 q two weeks given as a two-hour i.v. infusion. Clinical phase II experiences on the antitumoral activity of oxaliplatin have been conducted in hundreds of patients with advanced colorectal cancers (ACRC). Single agent activity reported as objective response rate in ACRC patients is 10% and 20% overall in ACRC patients with 5-fluorouracil (5-FU) pretreated/refractory and previously untreated ACRC, respectively. Synergistic cytotoxic effects in preclinical studies with thymidylate synthase inhibitors, cisplatin/carboplatin and topoisomerase I inhibitors, and the absence of hematologic dose-limiting toxicity have made oxaliplatin an attractive compound for combinations. Phase II trials combining oxaliplatin with 5-FU and folinic acid ACRC patients previously treated/refractory to 5-FU showed overall response rates ranging from 21% to 58%, and survivals ranging from 12 to 17 months. In patients with previously untreated ACRC, combinations of oxaliplatin with 5-FU and folinic acid showed response rates ranging from 34% to 67% and median survivals ranging from 15 to 19 months. Two randomized trials totaling 620 previously untreated patients with ACRC, comparing 5-FU and folinic acid to the same regimen with oxaliplatin, have shown a 34% overall response rate in the oxaliplatin group versus 12% in the 5-FU/folinic acid group for the first trial; and 51.2% vs. 22.6% in the second one. These statistically significant differences were confirmed in time to progression advantage for the oxaliplatin arm (8.7 vs. 6.1 months, and 8.7 vs. 6.1 months, respectively). A small but consistent number of histological complete responses have been reported in patients with advanced colorectal cancer treated with the combination of oxaliplatin with 5-FU/folinic acid, and secondary metastasectomy is increasingly done by oncologists familiar with the combination. Based on preclinical and clinical reports showing additive or synergistic effects between oxaliplatin and several anticancer drugs including cisplatin, irinotecan, topotecan, and paclitaxel, clinical trials of combinations with other compounds have been performed or are still ongoing in tumor types in which oxaliplatin alone showed antitumoral activity such as ovarian, non-small-cell lung, breast cancer and non-Hodgkin lymphoma. Its single agent and combination therapy data in ovarian cancer confirm its non-cross resistance with cisplatin/carboplatin. While the role of oxaliplatin in medical oncology is yet to be fully defined, it appears to be an important new anticancer agent.[1]
We have previously confirmed the in vitro activity of cisplatin and carboplatin against human melanoma cell lines. Both drugs are important components in the chemotherapy used in our service for advanced metastatic melanoma. In this communication we report the in vitro activity of oxaliplatin against human melanoma cell lines in comparison with cisplatin and carboplatin. Oxaliplatin was found to be active against C32 and G361 cell lines with IC50 values of 49.48 and 9.07 microM (1 h exposure), 9.47 and 1.30 microM (4 h exposure), and 0.98 and 0.14 microM (24 h exposure), respectively. The cytotoxic activity of oxaliplatin in this in vitro system appears to be significantly superior to that of carboplatin. Its activity becomes comparatively closer to that of cisplatin as exposure time increases. Indeed at a 24 h exposure oxaliplatin appears to be significantly more active than cisplatin against the G361 cell line (p=0.0343). Oxaliplatin merits evaluation in the clinic both as a single agent and in combination with other drugs active against melanoma.[2]
The in vitro cytotoxicity, protein binding, partitioning of platinum from whole blood into erythrocytes, its exchange back into plasma, and the in vitro biotransformation in plasma were studied for the new nonnephrotoxic platinum analogue oxaliplatin. The cytotoxicity studies were carried out against a panel of human tumor cell lines derived from carcinomas of the ovary (A2780, A2780/cp), bladder (TCCSUP, RT4), colon (HT-29), melanoma (SKMEL-2, HTB144), and glioma (U373MG and U87MG). The relative potency of the five platinum complexes was oxaliplatin = tetraplatin > cisplatin > iproplatin > carboplatin. Oxaliplatin was active against HT-29 and only minimally cross-resistant with cisplatin against A2780/cp. Both bladder carcinoma cell lines, both melanoma cell lines, and one of the two glioblastoma cell lines were resistant to both oxaliplatin and tetraplatin. The cytotoxicity profiles of the drug pairs oxaliplatin-tetraplatin and cisplatin-carboplatin showed statistically significant correlation by the Spearman rank correlation test. Oxaliplatin was similar to cisplatin and tetraplatin in protein binding; 85-88% of all platinum from oxaliplatin (5, 10, or 20 micrograms/ml) was bound to plasma proteins within the first 5 h with an average half-life of 1.71 +/- 0.06 h. When oxaliplatin was incubated in whole blood (5, 10, and 20 micrograms/ml), the erythrocytes took up 37.1 +/- 2.1% of the total platinum in 2 h (maximum uptake) which was not exchangeable into plasma. Thus the erythrocyte-bound fraction does not serve as a reservoir of drug. In plasma, oxaliplatin was unchanged at 0.5 h, but at 1 h, 30% of the total platinum in plasma was in a peak which had identical retention to that of (trans-1,2-diaminocyclohexane)dichloroplatinum(II), the major biotransformation product of tetraplatin. At 2 h, (trans-1,2-diaminocyclohexane)dichloroplatinum(II) and three other platinum-containing peaks were detected but no unchanged oxaliplatin. All the platinum eluted in a single peak near the solvent front at 4 h. The marked similarity in cytotoxicity between oxaliplatin and tetraplatin may be due to the formation of (trans-1,2-diaminocyclohexane)dichloroplatinum(II) in tissue culture media.[3]
Objective: The platinum-based chemotherapeutic agent oxaliplatin displays a wide range of antitumor activities. To date, no detailed data are available about the effects of oxaliplatin on hepatocellular carcinoma (HCC) cells. Herein, the anti-proliferation effects of oxaliplatin on HCCLM3 and Hep3B cells in vitro and in vivo are studied. Research methods: Cell viability was assessed by an MTT assay and apoptosis by flow cytometry and transmission electron microscopy. Apoptosis-related proteins in HCCLM3 cells were evaluated by microarray analysis, quantitative reverse transcriptase-PCR assay and western blotting. The effect of oxaliplatin was also studied in vivo using a xenograft model. Results: Oxaliplatin inhibited the growth of HCCLM3 and Hep3B cells. Using flow cytometry, transmission electron microscopy and the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay, we found that apoptosis was the main mechanism by which oxaliplatin inhibited tumor progression. Microarray analysis, quantitative reverse transcriptase-PCR and western blot analysis further demonstrated downregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL and upregulation of the pro-apoptotic protein Bax during oxaliplatin-induced apoptosis. Conclusions: The anti-proliferation effect of oxaliplatin in HCC cells is due to induction of apoptosis. Therefore, oxaliplatin may be an effective treatment for HCC and its use merits further in-depth investigation.[4]
A new platinum complex, oxalatoplatin or l-OHP, which, at the same metal dose in experimental tests is as efficient as cisplatin, and is more so at a lower metal dose than carboplatin; which is as efficient in human tumors of the testis and ovary as these other analogs, and more so in melanoma and breast cancer; which is not nephrotoxic, cardiotoxic or mutagenic, and hardly hematotoxic and neurotoxic, is described and compared with the above-mentioned platinum complexes. Combined with 5Fu, it induces a high number of remissions in colorectal cancer, and has brought about cures in inoperable gastric cancers. Combined with carboplatin, it has resulted in a high proportion of cures in L1210-carrying mice, which no other two-by-two combination of these complexes has achieved.[5]
Colon cancer is one of the most common malignancies in the world. Oxaliplatin, a third-generation platinum compound, is widely used in clinical chemotherapy of colon cancer. Although the mechanisms of the antitumor effect of Oxaliplatin have been investigated in recent years, the proteomic changes that are associated with the cellular response to this compound are poorly understood. In this study, we performed a comparative proteomic analysis to survey the global changes in protein expression levels after Oxaliplatin treatment in three colon cancer cell lines: HT29, SW620, and LoVo. Two-dimensional gel electrophoresis coupled with MALDI-TOF/TOF mass spectrometry revealed 57, 48, and 53 differentially expressed proteins in the three cell lines (HT29, SW620 and LoVo, respectively) after Oxaliplatin treatment. Of these proteins, 21 overlapped among all three cell lines. These overlapping proteins participate in many cellular processes, such as apoptosis, signal transduction, transcription and translation, cell structural organization, and metabolism. Additionally, the expression levels of ezrin (EZRI), heat-shock protein beta-1 (HSPB1), translationally controlled tumor protein (TCTP), and cell division control protein 2 homolog (CDC2) were confirmed by immunoblotting. This is the first direct proteomic analysis of Oxaliplatin-treated colon cancer cells. Several interesting proteins that we found warrant further investigation owing to their potential significant functions in the antitumor effect of Oxaliplatin.[8]
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C8H14N2O4PT
Molecular Weight
397.29
Exact Mass
397.06
Elemental Analysis
C, 24.19; H, 3.55; N, 7.05; O, 16.11; Pt, 49.10
CAS #
61825-94-3
Related CAS #
61825-94-3
PubChem CID
9887053
Appearance
White solid powder
Boiling Point
193.6ºC at 760 mmHg
LogP
0.614
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
6
Rotatable Bond Count
0
Heavy Atom Count
15
Complexity
191
Defined Atom Stereocenter Count
2
SMILES
[Pt+2].[O-]C(C(=O)[O-])=O.N([H])([H])[C@]1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])N([H])[H]
InChi Key
DRMCATBEKSVAPL-BNTLRKBRSA-N
InChi Code
InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
Chemical Name
[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
Synonyms
L-OHP; diaminocyclohexane oxalatoplatinum; oxalatoplatin; oxalatoplatinum; DTXSID0036760; Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II); cis-oxalato-trans-l-1,2-diaminocyclohexaneplatinum(II); US brand name: Eloxatin Foreign brand names: Dacotin; Dacplat; Eloxatine; Abbreviations: 1OHP; LOHP; Code names: JM83; RP54780; SR96669.
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
Note: Do not dissolve Oxaliplatin in DMSO, as platinum-based drugs are prone to deactivation in DMSO. Additionally, Oxaliplatin is not stable in solution and should be prepared immediately before use. DMSO has been reported to significantly inhibit or completely abolish the biological activity of Oxaliplatin.

DMF: <1.7 mg/mL
Water: <1~7 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
Note: Oxaliplatin is generally not recommended to be dissolved in DMSO, as platinum-based drugs are prone to deactivation in DMSO. Additionally, Oxaliplatin is not stable in solution and should be prepared immediately before use.

Solubility in Formulation 1: 1.92 mg/mL (4.83 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).

Solubility in Formulation 2: 3.33 mg/mL (8.38 mM) in 5% w/v Glucose Solution (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.5171 mL 12.5853 mL 25.1705 mL
5 mM 0.5034 mL 2.5171 mL 5.0341 mL
10 mM 0.2517 mL 1.2585 mL 2.5171 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
CTID: NCT05945823
Phase: Phase 2    Status: Recruiting
Date: 2024-12-02
Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
CTID: NCT06625320
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
CTID: NCT04847063
Phase: Phase 1    Status: Recruiting
Date: 2024-12-02
Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
CTID: NCT06381154
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-12-02
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
CTID: NCT05867121
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-12-02
View More

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
CTID: NCT05239741
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02


Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
CTID: NCT03675737
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-12-02
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
CTID: NCT04949256
Phase: Phase 3    Status: Recruiting
Date: 2024-12-02
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
CTID: NCT05067283
Phase: Phase 1    Status: Recruiting
Date: 2024-12-02
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
CTID: NCT04276493
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-11-29
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
CTID: NCT04047862
Phase: Phase 1    Status: Completed
Date: 2024-11-29
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene
CTID: NCT06704724
Phase: Phase 1    Status: Not yet recruiting
Date: 2024-11-29
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait
CTID: NCT05000697
Phase: N/A    Status: Recruiting
Date: 2024-11-27
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
CTID: NCT04083235
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-27
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients with Resectable Gastric Cancer
CTID: NCT03776487
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-27
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
CTID: NCT05286814
Phase: Phase 2    Status: Recruiting
Date: 2024-11-26
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
CTID: NCT03009058
Phase: Phase 1/Phase 2    Status: Terminated
Date: 2024-11-25
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
CTID: NCT03366155
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-25
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
CTID: NCT05849480
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-25
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
CTID: NCT05771480
Phase: Phase 3    Status: Recruiting
Date: 2024-11-25
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
CTID: NCT06538207
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-11-25
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
CTID: NCT03699319
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-11-22
PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
CTID: NCT05482893
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-11-22
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
CTID: NCT02997228
Phase: Phase 3    Status: Recruiting
Date: 2024-11-22
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
CTID: NCT05329766
Phase: Phase 2    Status: Recruiting
Date: 2024-11-21
Phase Ib Study of CBP-1019 in Combination with FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
CTID: NCT06576037
Phase: Phase 1    Status: Recruiting
Date: 2024-11-21
Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients with GI Malignancies
CTID: NCT06648785
Phase: Phase 2    Status: Enrolling by invitation
Date: 2024-11-21
Combination Chemotherapy and Bevacizumab with the NovoTTF-100L(P) System in Treating Participants with Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
CTID: NCT03203525
Phase: Phase 1    Status: Recruiting
Date: 2024-11-21
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
CTID: NCT05139017
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-11-21
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
CTID: NCT05564377
Phase: Phase 2    Status: Recruiting
Date: 2024-11-21
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
CTID: NCT03374254
Phase: Phase 1    Status: Completed
Date: 2024-11-21
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
CTID: NCT05564403
Phase: Phase 2    Status: Recruiting
Date: 2024-11-20
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
CTID: NCT06696768
Phase: Phase 1    Status: Not yet recruiting
Date: 2024-11-20
Neoadjuvant Therapy of HAIC(GEMOX) Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
CTID: NCT06208462
Phase: Phase 2    Status: Recruiting
Date: 2024-11-20
Botensilimab and Balstilimab Optimization in Colorectal Cancer
CTID: NCT06268015
Phase: Phase 2    Status: Recruiting
Date: 2024-11-20
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
CTID: NCT05836584
Phase: Phase 2    Status: Recruiting
Date: 2024-11-19
Pan Tumor Rollover Study
CTID: NCT03899155
Phase: Phase 2    Status: Recruiting
Date: 2024-11-19
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
CTID: NCT03615326
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-19
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
CTID: NCT04662710
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-18
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
CTID: NCT05152147
Phase: Phase 3    Status: Recruiting
Date: 2024-11-18
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
CTID: NCT04294264
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-18
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
CTID: NCT03505320
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-18
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma
CTID: NCT03784326
Phase: Phase 2    Status: Recruiting
Date: 2024-11-18
A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
CTID: NCT06586515
Phase: Phase 1    Status: Recruiting
Date: 2024-11-18
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CTID: NCT06624085
Phase: Phase 1    Status: Recruiting
Date: 2024-11-18
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
CTID: NCT05568095
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-15
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
CTID: NCT04210115
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-15
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
CTID: NCT04745988
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-15
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
CTID: NCT04281576
Phase: N/A    Status: Completed
Date: 2024-11-14
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
CTID: NCT04933227
Phase: Phase 2    Status: Terminated
Date: 2024-11-14
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
CTID: NCT04245865
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-14
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
CTID: NCT06532344
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-11-14
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
CTID: NCT01081262
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-13
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
CTID: NCT06205485
Phase: Phase 3    Status: Recruiting
Date: 2024-11-13
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
CTID: NCT01630083
Phase: Phase 2    Status: Completed
Date: 2024-11-13
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
CTID: NCT05253651
Phase: Phase 3    Status: Recruiting
Date: 2024-11-13
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
CTID: NCT00217737
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-12
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
CTID: NCT04607421
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-12
Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
CTID: NCT02578368
Phase: Phase 3    Status: Completed
Date: 2024-11-12
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
CTID: NCT06684158
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-12
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
CTID: NCT04615013
Phase: Phase 1    Status: Recruiting
Date: 2024-11-12
The Sagittarius Trial
CTID: NCT06490536
Phase: Phase 3    Status: Recruiting
Date: 2024-11-12
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
CTID: NCT02912559
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-11-12
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
CTID: NCT04447352
Phase: Phase 3    Status: Recruiting
Date: 2024-11-12
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
CTID: NCT06607185
Phase: Phase 1    Status: Recruiting
Date: 2024-11-12
A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer
CTID: NCT03813784
Phase: Phase 3    Status: Completed
Date: 2024-11-08
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
CTID: NCT05365581
Phase: Phase 1    Status: Recruiting
Date: 2024-11-08
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
CTID: NCT03193190
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-11-08
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
CTID: NCT06328738
Phase: Phase 1    Status: Recruiting
Date: 2024-11-08
Perioperative Chemotherapy in Gastric Cancer
CTID: NCT04937738
Phase: Phase 2    Status: Terminated
Date: 2024-11-06
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
CTID: NCT04539808
Phase: Phase 2    Status: Recruiting
Date: 2024-11-06
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
CTID: NCT04661150
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-06
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
CTID: NCT05863195
Phase: Phase 3    Status: Recruiting
Date: 2024-11-05
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
CTID: NCT04248452
Phase: Phase 3    Status: Recruiting
Date: 2024-11-05
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CTID: NCT06508658
Phase: Phase 3    Status: Recruiting
Date: 2024-11-05
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
CTID: NCT04068103
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-11-04
CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases
CTID: NCT05062317
Phase: Phase 2    Status: Recruiting
Date: 2024-11-04
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
CTID: NCT00680901
Phase: Phase 3    Status: Completed
Date: 2024-10-30
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
CTID: NCT04379596
Phase: Phase 2    Status: Recruiting
Date: 2024-10-30
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CTID: NCT04182204
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-30
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
CTID: NCT06662786
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-10-29
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
CTID: NCT06662877
Phase: Phase 2/Phase 3    Status: Not yet recruiting
Date: 2024-10-29
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
CTID: NCT04481204
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-28
CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC
CTID: NCT06652412
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-10-28
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
CTID: NCT05677490
Phase: Phase 3    Status: Recruiting
Date: 2024-10-26
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
CTID: NCT04340141
Phase: Phase 3    Status: Recruiting
Date: 2024-10-26
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
CTID: NCT03281369
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-10-26
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
CTID: NCT03777657
Phase: Phase 3    Status: Completed
Date: 2024-10-26
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
CTID: NCT05610163
Phase: Phase 2    Status: Recruiting
Date: 2024-10-26
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
CTID: NCT04522336
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-10-26
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
CTID: NCT03783442
Phase: Phase 3    Status: Completed
Date: 2024-10-26
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
CTID: NCT05379595
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-10-24
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
CTID: NCT05476796
Phase: Phase 2    Status: Recruiting
Date: 2024-10-24
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
CTID: NCT06123338
Phase: Phase 2    Status: Recruiting
Date: 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
CTID: NCT03469557
Phase: Phase 2    Status: Completed
Date: 2024-10-23
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
CTID: NCT04384484
Phase: Phase 3    Status: Recruiting
Date: 2024-10-23
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
CTID: NCT00335816
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-22
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
CTID: NCT04495296
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-10-21
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
CTID: NCT05007106
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-21
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
CTID: NCT03221426
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-18
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
CTID: NCT03929666
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-18
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
CTID: NCT01191697
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-17
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
CTID: NCT04408638
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-16
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
CTID: NCT04430738
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-10-15
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
CTID: NCT03533582
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-15
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
CTID: NCT02692248
Phase: Phase 2    Status: Completed
Date: 2024-10-10
A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer
CTID: NCT03504397
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-08
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
CTID: NCT06225999
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-08
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
CTID: NCT06628310
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-10-04
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
CTID: NCT04882241
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-04
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
CTID: NCT03653507
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-03
Preoperative Hypofractionated Radiotherapy with FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
CTID: NCT06078709
Phase: Phase 2    Status: Recruiting
Date: 2024-10-02
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
CTID: NCT06447662
Phase: Phase 1    Status: Recruiting
Date: 2024-10-01
An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
CTID: NCT05251948
Phase: Phase 1/Phase 2    Status: Active, not recruiting
Date: 2024-10-01
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
CTID: NCT05628038
Phase: Phase 2    Status: Recruiting
Date: 2024-10-01
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
CTID: NCT05026905
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-01
Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
CTID: NCT05688215
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-09-23
Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
CTID: NCT04488159
Phase: Phase 3    Status: Withdrawn
Date: 2024-09-20
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies
CTID: NCT02419495
Phase: Phase 1    Status: Terminated
Date: 2024-09-19
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
CTID: NCT06109467
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
CTID: NCT06493760
Phase: Phase 2 Stlse if

Biological Data
  • 6-Mercaptopurine (6-MP) Monohydrate(1)

    Oxaliplatin: Western blot analysis of survivin expression in untreated (A) and Oxaliplatin treated (B) HCT 116 whole cell lysates. Note down regulation of survivin expression in lane B. Antibody tested: survivin (D-8).
Contact Us